48
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.

      Nature chemical biology
      Acetylation, Alleles, Anilides, chemical synthesis, chemistry, pharmacology, Cell Line, Cells, Cultured, Dose-Response Relationship, Drug, Enzyme Inhibitors, therapeutic use, Friedreich Ataxia, drug therapy, genetics, Gene Expression Regulation, drug effects, Gene Silencing, HeLa Cells, Heterochromatin, Histone Deacetylase Inhibitors, Histones, metabolism, Humans, Iron-Binding Proteins, biosynthesis, Molecular Structure, RNA, Messenger, Transcription, Genetic

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Expansion of GAA x TTC triplets within an intron in FXN (the gene encoding frataxin) leads to transcription silencing, forming the molecular basis for the neurodegenerative disease Friedreich's ataxia. Gene silencing at expanded FXN alleles is accompanied by hypoacetylation of histones H3 and H4 and trimethylation of histone H3 at Lys9, observations that are consistent with a heterochromatin-mediated repression mechanism. We describe the synthesis and characterization of a class of histone deacetylase (HDAC) inhibitors that reverse FXN silencing in primary lymphocytes from individuals with Friedreich's ataxia. We show that these molecules directly affect the histones associated with FXN, increasing acetylation at particular lysine residues on histones H3 and H4 (H3K14, H4K5 and H4K12). This class of HDAC inhibitors may yield therapeutics for Friedreich's ataxia.

          Related collections

          Author and article information

          Comments

          Comment on this article